Cargando…

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

INTRODUCTION: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gérard, Alexandre, Romani, Serena, Fresse, Audrey, Viard, Delphine, Parassol, Nadège, Granvuillemin, Aurélie, Chouchana, Laurent, Rocher, Fanny, Drici, Milou-Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204701/ https://www.ncbi.nlm.nih.gov/pubmed/32418730 http://dx.doi.org/10.1016/j.therap.2020.05.002

Ejemplares similares

Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem
por: Fresse, Audrey, et al.
Publicado: (2021)

Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic
por: Romani, Serena, et al.
Publicado: (2020)

Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin
por: Gérard, Alexandre, et al.
Publicado: (2020)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021)

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database
por: Nguyen, Lee S., et al.
Publicado: (2020)

Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2023)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
por: Uzunova, Katya, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Brugada-like ECG pattern following off-label use: case report
Publicado: (2021)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
por: Purwati,, et al.
Publicado: (2021)

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders
Publicado: (2022)

Response to the editorial “COVID-19 in patients with cardiovascular diseases”: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)

Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

Are current guidelines adapted for patient eligibility to PrEP? A case report
por: Van Obberghen, Elise K., et al.
Publicado: (2019)

Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors
por: Bernier, Marjorie, et al.
Publicado: (2019)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
por: Schneider, Johanna, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

Azithromycin/lopinavir/ritonavir: Acute kidney injury following off label use: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Complete atrioventricular-block, torsades-de-pointes and QT-interval-prolongation following off label use: 2 case reports
Publicado: (2020)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
por: Habler, Katharina, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients
por: Gao, Guiju, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial
por: Nekoukar, Zahra, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Acute generalised exanthematous pustulosis with erythema multiforme-like lesions: case report
Publicado: (2020)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
por: Arabi, Yaseen M., et al.
Publicado: (2021)

A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
por: Maciorowski, Dawid, et al.
Publicado: (2020)

Hydroxychloroquine/chloroquine and azithromycin in COVID-19 patients: prospective study of electrical parameters
por: Ammor, Othmane, et al.
Publicado: (2021)

Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
por: Bakadia, Bianza Moise, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0lidvg6a6838mghanvg5mi7ouv